DV
Dividend Vision

SRZN — Surrozen Inc

Surrozen Inc (SRZN)

Total return is -84.2% over the past 5.6 years, 205.0 points behind SPY at 120.8%. Its deepest 1-year drawdown was 43.7%.

Surrozen is a biotechnology company that discovers and develops antibody-based therapeutics targeting the Wnt pathway to treat diseases including diabetic macular edema, age-related macular degeneration, and various other conditions affecting the eye, intestine, liver, lung, and other organs. The company does not currently distribute dividends. Surrozen appeals to investors seeking exposure to early-stage biopharmaceutical development rather than current income.

SRZN key facts

Asset type
Stock
Asset class
Equity
Inception date
01/11/2021
Last close
$23.96
Market cap
$257,285,824
Average volume
212900.0
Beta
0.508
Payout ratio
0.0
Forward P/E
0.0
EPS
$-36.59